Oncolytic virus therapy uses modified viruses to infect and destroy brain tumor cells directly. Unlike most immunotherapy, this approach also attacks the tumor physically, not only through immune activation.
This guide explains how these viruses work, reviews the only approved product worldwide, and covers ongoing research. It also explains realistic safety expectations for patients.
What Is Oncolytic Virus Therapy?
Oncolytic viruses selectively infect and replicate inside cancer cells. Scientists engineer these viruses so healthy cells resist infection, while tumor cells cannot defend themselves as effectively.
Consequently, the virus multiplies within the tumor and eventually bursts the cancer cells open. This process, called lysis, also releases tumor antigens that can alert the wider immune system.
How Oncolytic Viruses Attack Glioblastoma
Researchers engineer these viruses from existing, well-studied virus families. Herpes simplex virus and adenovirus serve as common starting points for glioblastoma research.
- Genetic modifications prevent the virus from replicating in healthy brain tissue.
- The virus replicates rapidly inside tumor cells, eventually destroying them directly.
- Cell death releases tumor antigens, which can turn a “cold” tumor “hot.”
- This shift may help other immune therapies, like checkpoint inhibitors, work better afterward.
Therefore, oncolytic viruses often work through two mechanisms at once, direct cell killing and immune activation.
A Brief History of Oncolytic Virus Research
Doctors first observed cancer regression after natural viral infections nearly a century ago. However, uncontrolled viral infection was far too dangerous for routine use at that time.
Subsequently, genetic engineering allowed scientists to weaken viruses safely while keeping their cancer-killing ability. This breakthrough eventually produced the first approved oncolytic products for melanoma and, later, brain tumors.
Delytact: The First Approved Oncolytic Virus for Brain Tumors
In June 2021, Japan’s health ministry approved teserpaturev, known commercially as Delytact, for malignant glioma. This decision marked the world’s first regulatory approval of an oncolytic virus for any primary brain tumor.
Teserpaturev is a triple-mutated herpes simplex virus, engineered specifically to replicate only within cancer cells. Doctors in Japan can now prescribe it for residual or recurrent malignant glioma under conditional approval.
Reviewing the Delytact Clinical Trial
Japanese researchers based this approval on a single-arm Phase 2 trial involving a small group of patients. Notably, the trial reported a one-year survival rate of 92.3 percent among these 13 patients.
| Trial Feature | Detail |
|---|---|
| Virus | Teserpaturev (G47Δ), triple-mutated HSV-1 |
| Trial design | Single-arm Phase 2 study |
| Patient number | 13 patients with residual or recurrent glioblastoma |
| Reported outcome | 92.3% one-year survival rate in this small group |
However, this trial’s small size means larger studies should confirm these encouraging early results before drawing broader conclusions.
Other Oncolytic Viruses in Development
Several other oncolytic viruses continue advancing through trials outside Japan. For example, DNX-2401, an engineered adenovirus, has shown tumor responses in some Phase I glioblastoma patients.
Similarly, PVSRIPO, a modified poliovirus, gained attention after early Duke University trials reported some long-term survivors. Meanwhile, researchers also study modified reovirus and additional herpes-based viruses in ongoing programs.
FDA and Global Approval Status
No oncolytic virus currently holds FDA approval for glioblastoma or any brain tumor in the United States. Japan remains the only country with a formal approval specifically for malignant glioma.
Consequently, American and European patients can generally access these therapies only through registered clinical trials. Approval status may shift as ongoing studies mature, so patients should always verify current status directly.
Who Might Be a Candidate
Candidacy depends heavily on tumor location, prior treatment, and overall health. Doctors typically consider oncolytic virus therapy for tumors accessible enough for direct injection.
- Recurrent glioblastoma after standard surgery, radiation, and chemotherapy
- Tumor location suitable for direct or catheter-guided injection
- No active, uncontrolled infection or severe immune suppression
- Willingness to comply with post-injection isolation precautions
Therefore, imaging and a detailed medical history should guide this decision closely.
PVSRIPO: The Modified Poliovirus Approach
PVSRIPO combines part of poliovirus with part of a common cold virus, creating a hybrid that cannot cause paralysis. Duke University researchers pioneered this approach for recurrent glioblastoma.
Early trial data drew wide public attention after some long-term survivors emerged unexpectedly. Nevertheless, this remains an investigational therapy, and larger trials continue evaluating its true benefit.
Oncolytic Viruses Compared With Other Immunotherapy
Oncolytic viruses attack tumors differently from vaccines or checkpoint inhibitors. Our dendritic cell vaccine guide explains a purely immune-based alternative.
| Therapy | Core Mechanism | Approval Status |
|---|---|---|
| Oncolytic virus therapy | Directly infects and destroys tumor cells | Approved in Japan only |
| Dendritic cell vaccine | Trains immune cells using tumor material | Phase 3 data reported, review ongoing |
| Checkpoint inhibitors | Removes brakes on existing immune cells | Mostly negative Phase 3 results |
Consequently, researchers now test whether combining these mechanisms outperforms any single approach alone.
Combining Oncolytic Viruses With Other Therapies
Several trials pair oncolytic viruses with checkpoint inhibitors directly. Since the virus turns the tumor “hot,” the checkpoint drug can then act on a larger population of activated immune cells.
Additionally, some research groups explore delivering CAR-T target antigens through an oncolytic virus first. Our CAR-T cell therapy guide and checkpoint inhibitor guide explain these companion approaches.
Side Effects of Oncolytic Virus Therapy
Most patients tolerate oncolytic virus therapy reasonably well. Typical reactions resemble a mild viral illness rather than a severe systemic event.
- Fever and chills shortly after injection
- Fatigue and mild headache for a few days
- Localized brain swelling near the injection site
- Rare risk of seizures linked to inflammation around the tumor
Nevertheless, doctors monitor patients closely after injection given the brain’s sensitivity to swelling. Our immunotherapy side effects guide covers this monitoring process in more depth.
Why Researchers Chose These Specific Viruses
Not every virus makes a good oncolytic candidate. Researchers generally look for viruses that naturally prefer dividing cells, since cancer cells divide far more often than healthy brain tissue.
Additionally, scientists favor viruses with well-understood biology, since decades of research on herpes and polio, for example, made genetic engineering safer and more predictable.
Safety Precautions and Viral Shedding
Because oncolytic viruses remain live, modified organisms, doctors take specific precautions around treatment. Patients may need to limit close contact with immunocompromised individuals for a defined period.
Additionally, healthcare staff follow standard infection control procedures during injection and follow-up visits. Therefore, patients should discuss these practical precautions with their care team beforehand.
Choosing a Center for Oncolytic Virus Trials
Patients should confirm any oncolytic virus trial appears on a public registry before enrolling. Furthermore, ask whether the surgical team has direct experience with intratumoral injection procedures.
A second opinion from an independent neuro-oncology specialist often clarifies whether this approach truly fits a patient’s tumor location. Our team reviews cases through our contact page.
What to Expect During Treatment
Doctors typically deliver oncolytic viruses directly into the tumor or surrounding tissue.
- Imaging confirms the tumor’s exact location and accessibility.
- Doctors inject the virus during surgery or through a guided catheter procedure.
- The care team monitors patients closely for several days afterward.
- Follow-up MRI scans track tumor response over the following weeks and months.
Consequently, this treatment often pairs naturally with a planned surgical procedure.
Why Location in the Brain Matters
Tumor location strongly influences whether oncolytic virus injection is feasible. Tumors near critical structures may limit direct access without unacceptable risk.
Consequently, a detailed imaging review always precedes any decision to pursue this therapy. Our guide to understanding glioblastoma explains how tumor location shapes treatment planning more broadly.
Cost and Access Considerations
Trial sponsors typically cover the virus product and required monitoring visits. However, patients still pay separately for travel, lodging, and any standard-of-care treatment received alongside the trial.
Consequently, patients considering treatment abroad should request a clear cost breakdown before enrolling in any program.
Setting Realistic Expectations
The Delytact approval represents genuine progress, yet it rests on a small trial. Larger, controlled studies still need to confirm this survival benefit across broader patient populations.
Therefore, patients should view oncolytic virus therapy as a promising, evolving option rather than a proven cure. A specialist can help place these results in proper context for your specific case.
Key Terms Explained
- Oncolysis: The process of a virus destroying a cancer cell by causing it to burst.
- Intratumoral injection: Delivering a treatment directly into the tumor tissue.
- Viral shedding: The release of virus particles from a treated patient’s body.
- Conditional approval: A time-limited regulatory approval requiring further confirmatory data.
Frequently Asked Questions
Is oncolytic virus therapy approved for brain tumors?
Only in Japan, where teserpaturev received conditional approval in 2021. Other countries still treat this therapy as investigational.
How does an oncolytic virus reach a brain tumor?
Doctors typically inject the virus directly during surgery or through a carefully guided catheter procedure into the tumor bed.
Can healthy brain tissue get infected by the virus?
Researchers engineer these viruses specifically to limit replication in healthy cells. However, doctors still monitor patients closely for any unexpected reaction.
Is oncolytic virus therapy contagious to family members?
Doctors advise reasonable precautions around immunocompromised contacts for a defined period. Ask your care team about specific guidance for your situation.
Can oncolytic viruses be combined with checkpoint inhibitors?
Yes, several trials test this combination directly, since the virus may help checkpoint drugs work more effectively afterward.
Where can international patients learn about oncolytic virus trials?
Contact our clinic through the contact page to discuss eligibility and coordinate a specialist review.
How long do doctors monitor a patient after oncolytic virus injection?
Close monitoring typically continues for one to two weeks, followed by regular imaging over the following months to track response.
Does oncolytic virus therapy replace surgery?
No, doctors usually deliver the virus during or after surgical tumor removal, rather than instead of surgery.
Reviewed by Prof. Dr. Serdar Baki Albayrak, Neurosurgeon, Istanbul, Turkey.
Medical Disclaimer: This article provides general information only and does not replace professional medical diagnosis or treatment. Please consult Prof. Dr. Serdar Baki Albayrak or another qualified physician directly to discuss your specific condition.
Request an Appointment
Do you have questions about your diagnosis or treatment options? Send your details below, and our team will contact you to schedule a consultation.
